Latest:
Congress Passed the Stimulus Bill; What Should You Do Now?
Physicians who see Medicare patients are practicing in very difficult times.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Alberto Chiappori MD
Alberto Chiappori, MD, is a senior member of Oncology and Medicine for the Thoracic Oncology Program at the H. Lee Moffitt Cancer Center and Research Institute.
Latest:
Dr Chiappori on the Role of Ensartinib for ALK+ NSCLC With CNS Metastases
Alberto Chiappori, MD, discusses the inclusion of patients with CNS metastases in the eXALT3 trial of ensartinib in ALK-positive NSCLC.
Alberto Montero, MD
Latest:
Dr. Montero Discusses PERTAIN Study in HER2-Positive Breast Cancer
Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.
Aldo J. Montano-Loza, MD, MSc, PhD
Latest:
Dr. Montano-Loza on Link Between HCC Risk and High Visceral Adipose Tissue
Aldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.
Aleix Prat, MD, PhD
Latest:
Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment
Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.
Alex A. Adjei, MD, PhD
Latest:
Dr. Adjei on Adverse Events From MEK Inhibitors
Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.
Alexander B. Olawaiye, MD
Alexander B. Olawaiye, MD, is a professor in the Department of Obstetrics & Reproductive Sciences at the University of Pittsburgh, as well as the director of gynecologic cancer research at Magee-Women’s Hospital of the University of Pittsburgh Medical Center
Latest:
Dr Olawaiye on Next Steps for Investigating Relacorilant in Platinum-Resistant Ovarian Cancer
Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Alexander Drilon, MD
Alexander Drilon, MD, is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center
Latest:
Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.